{"id":"NCT00528606","sponsor":"Endo Pharmaceuticals","briefTitle":"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture","officialTitle":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Dupuytren's Contracture","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2007-09-12","resultsPosted":"2010-10-22","lastUpdate":"2017-12-02"},"enrollment":308,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dupuytren's Contracture"],"interventions":[{"type":"BIOLOGICAL","name":"collagenase clostridium histolyticum","otherNames":["XIAFLEX®","AA4500"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"AA4500 0.58 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This was a Phase 3, double-blind, randomized, placebo-controlled study conducted in the United States. Subjects with a diagnosis of Dupuytren's contracture in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint that resulted in a fixed flexion deformity of at least one finger, other than the thumb, that was at least 20° as measured by finger goniometry and was suitable for injection were randomized 2:1 to receive AA4500 0.58 mg or placebo.\n\nThis study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.","primaryOutcome":{"measure":"Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection","timeFrame":"Within 30 days after the last injection","effectByArm":[{"arm":"AA4500 0.58 mg","deltaMin":64,"sd":null},{"arm":"Placebo","deltaMin":6.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["21967070","19726771"],"seeAlso":["http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125338lbl.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":204},"commonTop":["Oedema peripheral","Contusion","Injection site haemorrhage","Injection site pain","Pain in extremity"]}}